Your shopping cart is currently empty

LY2510924 is an effective and selective CXCR4 antagonist. It blocks SDF-1 binding to CXCR4 (IC50: 0.079 nM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $797 | 7-10 days | 7-10 days | |
| 50 mg | $1,280 | 7-10 days | 7-10 days | |
| 100 mg | $1,940 | 7-10 days | 7-10 days |
| Description | LY2510924 is an effective and selective CXCR4 antagonist. It blocks SDF-1 binding to CXCR4 (IC50: 0.079 nM). |
| Targets&IC50 | SDF-1α-CXCR4:49.5 pM (ki), SDF-1α-CXCR4:79.7 pM |
| In vitro | LY2510924 inhibits SDF-1–induced cell migration (IC50: 0.26 nM) and inhibits SDF-1/CXCR4-mediated intracellular signaling, in human lymphoma U937 cells expressing endogenous CXCR4. LY2510924 also inhibits SDF-1–induced GTP binding (Kb: 0.38 nM). LY2510924 specifically blocks SDF-1 binding to CXCR4 (IC50: 0.079 nM). LY2510924 displays a concentration-dependent inhibition of SDF-1–stimulated phospho-ERK and phospho-Akt in tumor cells. Biochemical and cellular analyses reveal that LY2510924 has no apparent agonist activity[1]. LY2510924 chiefly inhibits the proliferation of AML cells with little induction of cell death and reduces protection against chemotherapy by stromal cells[2]. |
| Molecular Weight | 1189.45 |
| Formula | C62H88N14O10 |
| Cas No. | 1088715-84-7 |
| Smiles | [H][C@]1(CCCNC(N)=N)NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@]([H])(Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@H](Cc2ccc3ccccc3c2)NC1=O)C(=O)N[C@@H](CCCCNC(C)C)C(N)=O |
| Relative Density. | 1.33 g/cm3 (Predicted) |
| Sequence | N(1)Phe-D-Tyr-Lys(iPr)-D-Arg-2Nal-Gly-D-Glu(1)-Lys(iPr)-NH2 |
| Sequence Short | FYKRGEK |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (105.09 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (2.77 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.